Gonal-F Rff
Product manufactured by Emd Serono, Inc.
Indications and Purposes
| Indications And Usage Gonal-F ® Rff (Follitropin Alfa For Injection) Is Indicated For The Induction Of Ovulation And Pregnancy In The Oligo-Anovulatory Infertile Patient In Whom The Cause Of Infertility Is Functional And Not Due To Primary Ovarian Failure. Gonal-F ® Rff Is Also Indicated For The Development Of Multiple Follicles In The Ovulatory Patient Participating In An Assisted Reproductive Technology (Art) Program. Selection Of Patients Before Treatment With Gonal-F ® Rff Is Instituted, A Thorough Gynecologic And Endocrinologic Evaluation Must Be Performed. This Should Include An Assessment Of Pelvic Anatomy. Patients With Tubal Obstruction Should Receive Gonal-F ® Rff Only If Enrolled In An In Vitro Fertilization Program. Primary Ovarian Failure Should Be Excluded By The Determination Of Gonadotropin Levels. Appropriate Evaluation Should Be Performed To Exclude Pregnancy. Patients In Later Reproductive Life Have A Greater Predisposition To Endometrial Carcinoma As Well As A Higher Incidence Of Anovulatory Disorders. A Thorough Diagnostic Evaluation Should Always Be Performed In Patients Who Demonstrate Abnormal Uterine Bleeding Or Other Signs Of Endometrial Abnormalities Before Starting Gonal-F ® Rff Therapy. Evaluation Of The Partner's Fertility Potential Should Be Included In The Initial Evaluation. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Follitropin Alfa |